Randomized controlled trials (RCTs) remain the cornerstone of causal inference on the safety and efficacy of medicinal products. But their limited follow-up, controlled settings, and narrowly defined data collection to balance the burden to patients and maintain study feasibility often results in unaddressed important...
A. Meinecke, J. Diaz-Decaro, Kathleen M. Gavin et al.· Frontiers in Pharmacology· 1 citation
Key Points Public health faces increasingly complex challenges for pharmacoepidemiology: monitoring and evaluating the safety and effectiveness of medicines in real‐world populations, predicting and responding to emerging diseases and outbreaks, overcoming inequities in drug access and outcomes, managing risks from wid...
G. Sarri, J. Diaz-Decaro, M. Burcu et al.· Pharmacoepidemiology and Dru...· 0 citations
RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making and methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and no...
Le Su, Lei Chen, R. Mamtani et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.